

Delivering tAN to Reduce HMB: The LUNA Study

NCT07326722

Status	RECRUITING
Phase	Not Applicable
Sponsor	Spark Biomedical, Inc.
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (6)

- Regularly menstruating female aged 14-45 years at time of screening
 - History of menorrhagia as assessed by the Menorrhagia Screening Tool
 - Stable/consistent use of current non-hormonal medications and supplements for the past three months, willingness to continue use for duration of study, and not start any new medications or homeopathic remedies
 - Reliable access to an internet-enabled device to complete required questionnaires that is compatible with the study application (iOS 18 and Android 15 or greater)
 - Willingness to consistently use only study-provided menstrual products throughout duration of the study
- ... and 1 more (see full listing online)

Exclusion (24)

- Pregnancy within three months of enrollment
 - Lactating at the time of enrollment
 - Typical length of menstruation greater than 14 days
 - Antifibrinolytic (i.e. tranexamic acid; Lysteda) use within 14 days of enrollment
 - Known acquired bleeding disorder
- ... and 19 more (see full listing online)

Locations (1 total)

Lindus Health - DECENTRALIZED STUDY, Boston, Massachusetts, United States